| Literature DB >> 32403397 |
Andrea Ferrigno1, Laura G Di Pasqua1, Giuseppina Palladini1,2, Clarissa Berardo1, Roberta Verta3, Plinio Richelmi1, Stefano Perlini1,4, Debora Collotta3, Massimo Collino3, Mariapia Vairetti1.
Abstract
In this study, we demonstrated the involvement of matrix metalloproteinases (MMPs) in hepatic ischemia/reperfusion (I/R) injury. Our aim is to evaluate the impact of reperfusion on I/R-related changes in RECK, an MMP modulator, and mitogen-activated protein kinase (MAPKs) pathways (ERK, p38, and JNK). Male Wistar rats were either subjected to 60 min partial-hepatic ischemia or sham-operated. After a 60 min or 120 min reperfusion, liver samples were collected for analysis of MMP-2 and MMP-9 by zymography and RECK, TIMP-1, and TIMP-2 content, MAPKs activation (ERK1/2, JNK1/2, and p38), as well as iNOS and eNOS by Western blot. Serum enzymes AST, ALT, and alkaline-phosphatase were quantified. A transitory decrease in hepatic RECK and TIMPs was associated with a transitory increase in both MMP-2 and MMP-9 activity and a robust activation of ERK1/2, JNK1/2, and p38 were detected at 60 min reperfusion. Hepatic expression of iNOS was maximally upregulated at 120 min reperfusion. An increase in eNOS was detected at 120 min reperfusion. I/R evoked significant hepatic injury in a time-dependent manner. These findings provide new insights into the underlying molecular mechanisms of reperfusion in inducing hepatic injury: a transitory decrease in RECK and TIMPs and increases in both MAPK and MMP activity suggest their role as triggering factors of the organ dysfunction.Entities:
Keywords: MAPKs; RECK; eNOS; iNOS.; ischemia/reperfusion; matrix metalloproteinase
Mesh:
Substances:
Year: 2020 PMID: 32403397 PMCID: PMC7277810 DOI: 10.3390/biom10050747
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Serum levels of AST, ALT, ALP (U/L), and total and direct bilirubin (mg/dL).
| Sham 60/60 | I/R 60/60 | Sham 60/120 | I/R 60/120 | |
|---|---|---|---|---|
| AST | 243 ± 57 | 3444 ± 1062 | 198 ± 43 | 10,387 ± 1158 * |
| ALT | 66 ± 19 | 3830 ± 961 | 61 ± 28 | 9320 ± 1040 * |
| ALP | 431 ± 50 | 605 ± 51 | 417 ± 55 | 769 ± 29 * |
| Total Bilirubin | 0.13 ± 0.024 | 0.25 ± 0.070 | 0.12 ± 0.011 | 0.35 ± 0.043 |
| Direct Bilirubin | 0.045 ± 0.019 | 0.17 ± 0.032 | 0.04 ± 0.024 | 0.18 ± 0.013 |
Aspartate transaminase, AST; alanine transaminase, ALT; alkaline phosphatase, ALP; * p < 0.05.
Figure 1Liver histology at the end of reperfusion. Paraplast-embedded sections were cut at 7 μm and stained with H&E. Panel (A) and (C): 60/60 and 60/120 min sham-operated rats, respectively. Panel (B) and (D): rats submitted to ischemia followed by 60 or 120 min reperfusion, respectively.
Figure 2Hepatic MMP-2 and MMP-9 activity, RECK, TIMP-1, and TIMP-2 at the end of ischemia and after 60 min or 120 min of reperfusion. Panel (A): RECK, * p = 0.02; Panel (B): MMP-2, * p = 0.006; MMP-9: * p = 0.007; Panel (C): TIMP-1 * p = 0.04; TIMP-2, * p = 0.03. The results are reported as the mean ± SE of 6 different experiments. RECK, reversion-inducing cysteine-rich protein with Kazal motifs; TIMPs, tissue inhibitor of metalloproteinases.
Figure 3Hepatic MAPK pathways (ERK1/2, JNK1/2 and p38) at the end of ischemia and after 60 min or 120 min reperfusion. Panel (A): ERK1, * p = 0.025; ERK2, * p = 0.025; Panel (B): JNK1, * p = 0.028; JNK2, * p = 0.043; Panel (C): P-38, * p = 0.014. The results are reported as the mean ± SE of 6 different experiments.
Figure 4Hepatic eNOS and iNOS at the end of reperfusion. Panel (A): eNOS, * p = 0.002; Panel (B): iNOS, * p = 0.004. The results are reported as the mean ± SE of 6 different experiments.